BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over
This article was originally published in The Pink Sheet Daily
Seeing no clear path to approval in the US or Europe for its muscular dystrophy drug drisapersen, BioMarin shelves it , plus three first-generation follow-on products. But it continues to "explore" its early stage next-generation oligonucleotides as potential treatments for DMD.
Register for our free email digests: